[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  BioCentury [@BioCentury](/creator/twitter/BioCentury) on x 16.2K followers Created: 2025-07-15 22:30:12 UTC Rare disease setbacks for Ultragenyx, mid-stage win for Rhythm. Plus: Astrazeneca and Takeda preparing submissions after Phase III readouts, in this week’s Clinical Report  XXX engagements  **Related Topics** [$azn](/topic/$azn) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/BioCentury/status/1945249566049095747)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
BioCentury @BioCentury on x 16.2K followers
Created: 2025-07-15 22:30:12 UTC
Rare disease setbacks for Ultragenyx, mid-stage win for Rhythm. Plus: Astrazeneca and Takeda preparing submissions after Phase III readouts, in this week’s Clinical Report
XXX engagements
Related Topics $azn stocks healthcare
/post/tweet::1945249566049095747